Lymphocyte-to-monocyte ratio effectively predicts survival outcome of patients with obstructive colorectal cancer

Table 5 Univariate and multivariate analyses of risk factors for survival outcomes in both emergency surgery and bridge to surgery groups

3-year overall survival	ES group (n = 90)				BTS group (n = 38)
	Univariate		Multivariate		Univariate		Multivariate
Characteristic	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value
CEA (≥ 5 ng/mL vs < 5 ng/mL)	1.48 (0.70-3.11)	0.303			2.53 (0.68-9.35)	0.165
ASA (Grade ≥ III vs Grade < III)	1.50 (0.72-3.11)	0.277			1.64 (0.45-5.96)	0.454
pT stage (pT3-4 vs pT1-2)	1.66 (0.72-3.83)	0.238			4.17 (1.09-15.95)	0.037
pN stage (pN+ vs pN0)	1.05 (0.51-2.19)	0.887			5.02 (0.65-38.66)	0.122
LVI (+) vs LVI (-)	1.30 (0.53-3.15)	0.568			3.78 (1.23-11.64)	0.020	3.52 (1.03-12.02)	0.045
NLR ≥ 19.3 vs NLR < 19.3	2.98 (1.27-6.97)	0.012
dNLR ≥ 1.57 vs dNLR < 1.57	2.40 (1.12-5.13)	0.024	2.34 (1.08-5.07)	0.032
PLR ≥ 155 vs PLR < 155	1.83 (0.70-4.79)	0.217
SII ≥ 3645 vs SII < 3645	1.61 (0.71-3.61)	0.252
LMR ≥ 1.67 vs LMR < 1.67					4.09 (1.12-14.87)	0.033	4.57 (0.98-21.38)	0.053
Chemotherapy (+) vs (-)	0.74 (0.36-1.51)	0.402			1.43 (0.47-4.38)	0.529

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; dNLR: Derived neutrophil-to-lymphocyte ratio; PLR: Platelet–to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; LVI: Lymphovascular invasion. P < 0.05 was considered significant.